Interleukin-1α mediates the antiproliferative effects of 1,25-dihydroxyvitamin D3 in prostate progenitor/stem cells

Cancer Research

Volumn 71, Issue 15, 2011, Pages 5276-5286

  Maund, Sophia L ^a   Barclay, Wendy W ^a   Hover, Laura D ^a   Axanova, Linara S ^a   Sui, Guangchao ^a   Hipp, Jason D ^a,d   Fleet, James C ^b   Thorburn, Andrew ^c   Cramer, Scott D ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b PURDUE UNIVERSITY   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CALCITRIOL; INTERLEUKIN 1ALPHA; SMALL INTERFERING RNA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STEM CELL; CELL AGING; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RESPONSE; EPITHELIUM CELL; GENE EXPRESSION PROFILING; GROWTH INHIBITION; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SYSTEMS BIOLOGY; UPREGULATION;

ANIMALS; CALCITRIOL; CELL AGING; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; GENE EXPRESSION REGULATION; GENES, P16; GENES, RETINOBLASTOMA; INTERLEUKIN-1ALPHA; MALE; MICE; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE; RECEPTORS, CALCITRIOL; RNA, SMALL INTERFERING; STEM CELLS;

EID: 79960932331     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2160     Document Type: Article

References (49)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Trottier G, Bostrom PJ, Lawrentschuk N, Fleshner NE. Nutraceuticals and prostate cancer prevention: a current review. Nat Rev Urol 2010;7:21-30.
3. Trump D, Deeb K, Johnson C. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J 2010;16:1-9.
4. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? [Hypothesis]. Anticancer Res 1990;10:1307-11.
5. Rao A, Woodruff RD, Wade WN, Kute TE, Cramer SD. Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. J Nutr 2002;132:3191-4.
6. Flores O, Wang Z, Knudsen K, Burnstein K. Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology 2010;151:896-908.
7. Rao A, Coan A, Welsh JE, Barclay WW, Koumenis C, Cramer SD. Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells. Cancer Res 2004;64:2143-7. (Pubitemid 38339465)
8. Wade WN, Willingham MC, Koumenis C, Cramer SD. p27Kip1 is essential for the antiproliferative action of 1,25-dihydroxyvitamin D3 in primary, but not immortalized, mouse embryonic fibroblasts. J Biol Chem 2002;277:37301-6.
9. Yang ES, Burnstein KL. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 2003;278:46862-8. (Pubitemid 37452267)
10. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 1997;19:15-27. (Pubitemid 27345239)
11. Krishnan A, Trump D, Johnson C, Feldman D. The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin North Am 2010;39:401-18.
12. Tokar EJ, Webber MM. Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. Clin Exp Metastasis 2005;22:265-73. (Pubitemid 41298008)
13. Esquenet M, Swinnen JV, Heyns W, Verhoeven G. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 1996;28:182-94.
14. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Saeid MS, et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999;53:939-44. (Pubitemid 29196309)
15. Barclay WW, Axanova LS, Chen W, Romero L, Maund SL, Soker S, et al. Characterization of adult prostatic progenitor/stem cells exhibiting self-renewal and multilineage differentiation. Stem Cells 2008;26:600-10.
16. Leong K, Wang B, Johnson L, Gao W. Generation of a prostate from a single adult stem cell. Nature 2008;456:804-8.
17. Lawson D, Xin L, Lukacs R, Cheng D, Witte O. Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci U S A 2007;104:181-6. (Pubitemid 46068005)
18. Collins A, Berry P, Hyde C, Stower M, Maitland N. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-51. (Pubitemid 41713363)
19. Wang X, Kruithof-de Julio M, Economides K, Walker D, Yu H, Halili M, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009;461:495-500.
20. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11. (Pubitemid 33041634)
21. Maund SL, Cramer SD. The tissue-specific stem cell as a target for chemoprevention. Stem Cell Rev 2010;7:307-14.
22. Barclay WW, Cramer SD. Culture of mouse prostatic epithelial cells from genetically engineered mice. Prostate 2005;63:291-8. (Pubitemid 40571063)
23. Stec D, Davisson R, Haskell R, Davidson B, Sigmund C. Efficient liverspecific deletion of a floxed human angiotensinogen transgene by adenoviral delivery of cre recombinase in vivo. J Biol Chem 1999;274:21285-90.
24. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9. (Pubitemid 17064313)
25. Irazarry R, Bolstad B, Ciollin F, Cope L, Hobbs B, Speed T. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
26. Irazarry R, Hobbs B, Collin F, Beazer-Barclay Y, Antonellis K, Sherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
27. Lockhart D, Dong H, Byrne M, Folettie M, Gallo M, Chee M, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996;14:1675-80. (Pubitemid 26414810)
28. Sui G, Shi Y. Gene silencing by a DNA vector-based RNAi technology. Methods Mol Biol 2005;309:205-18.
29. Seals D, Azucena EJ, Pass I, Tesfay L, Gordon R, Woodrow M, et al. The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell 2005;7:155-65. (Pubitemid 40248341)
30. Axanova LS, Chen YQ, McCoy T, Sui G, Cramer SD. 1,25-Dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells. Prostate 2010;70:1658-71.
31. Li J, Fleet JC, Teegarden D. Activation of rapid signaling pathways does not contribute to 1 alpha,25-dihydroxyvitamin D3-induced growth inhibition of mouse prostate epithelial progenitor cells. J Cell Biochem 2009;107:1031-6.
32. Kato S, Takeyama K, Kitanaka S, Murayama A, Sekine K, Yoshizawa T. In vivo function of VDR in gene expression-VDR knock-out mice. J Steroid Biochem Mol Biol 1999;69:247-51. (Pubitemid 29305542)
33. Kovalenko PL, Zhang Z, Cui M, Clinton SK, Fleet JC. 1,25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genomics 2010;11:26.
34. Hsieh TY, Ng CY, Mallouh C, Tazaki H, Wu JM. Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells. Biochem Biophys Res Commun 1996;223:141-6. (Pubitemid 26202490)
35. Zhao XY, Ly LH, Peehl DM, Feldman D. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 1997;138:3290-8. (Pubitemid 27345681)
36. Zhao XY, Ly LH, Peehl DM, Feldman D. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999;140:1205-12. (Pubitemid 29104222)
37. Tran C, Lin C, Yamashiro J, Reiter R. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 2002;1:113-21. (Pubitemid 36306769)
38. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006;25:387-408. (Pubitemid 44922357)
39. Kavita U, Mizel SB. Differential sensitivity of interleukin-1 alpha and -beta precursor proteins to cleavage by calpain, a calcium-dependent protease. J Biol Chem 1995;270:27758-65.
40. Stevenson FT, Bursten SL, Fanton C, Locksley RM, Lovett DH. The 31-kDa precursor of interleukin 1 alpha is myristoylated on specific lysines within the 16-kDa N-terminal propiece. Proc Natl Acad Sci U S A 1993;90:7245-9. (Pubitemid 23222426)
41. Lee SK, Kalinowski J, Jastrzebski S, Lorenzo JA. 1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. J Immunol 2002;169: 2374-80. (Pubitemid 34920979)
42. Kong J, Grando SA, Li YC. Regulation of IL-1 family cytokines IL-1alpha, IL-1 receptor antagonist, and IL-18 by 1,25-dihydroxyvitamin D3 in primary keratinocytes. J Immunol 2006;176:3780-7. (Pubitemid 43364026)
43. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008;14:146-55.
44. Ricote M, Garcia-Tunon I, Bethencourt FR, Fraile B, Paniagua R, Royuela M. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 2004;100:1388-96. (Pubitemid 38366841)
45. Colnot S, Lambert M, Blin C, Thomasset M, Perret C. Identification of DNA sequences that bind retinoid X receptor-1,25(OH)2D3-receptor heterodimers with high affinity. Mol Cell Endocrinol 1995;113:89-98.
46. St-Arnaud R, Candeliere GA, Dedhar S. New mechanisms of regulation of the genomic actions of vitamin D in bone cells: interaction of the vitamin D receptor with non-classical response elements and with the multifunctional protein, calreticulin. Front Biosci 1996;1:d177-88.
47. Chen KS, DeLuca HF. Cloning of the human 1 alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim Biophys Acta 1995;1263:1-9.
48. Peng L, Malloy PJ, Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 2004;18:1109-19. (Pubitemid 38591278)
49. Kanakaraj P, Schafer PH, Cavender DE, Wu Y, Ngo K, Grealish PF, et al. Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production. J Exp Med 1998;187:2073-9. (Pubitemid 28285577)